

PRODUCT PIPELINE

IMiDs® Compounds:

REVLIMID®: Multiple Myeloma (US)				
REVLIMID: MDS deletion 5Q (US)				
REVLIMID: Multiple Myeloma (EMEA)				
REVLIMID: MDS deletion 5Q (EMEA)				
REVLIMID: Multiple Myeloma (SWISS)				
REVLIMID: MDS deletion 5Q (SWISS)				
REVLIMID: MDS				
REVLIMID: CLL				
REVLIMID: NHL				
REVLIMID: Solid Tumors				
pomalidomide (CC-4047): Myelofibrosis				
pomalidomide (CC-4047): Multiple Myeloma				
pomalidomide (CC-4047): Solid Tumors				
pomalidomide (CC-4047): Sickle Cell Anemia				
CC-11006: MDS				
CC-10015: Rheumatology				
CC-16057: Oncology/Inflammation				

THALOMID®:

Multiple Myeloma (US)				
ENL				

Thalidomide Pharmion 50 MG:

Multiple Myeloma (EMEA)				
Other Cancer				

VIDAZA® (azacitidine):

MDS (US)				
MDS (EMEA)				
AML				
Solid Tumors				
MDS/AML (Oral azacitidine)				

ALKERAN®:

Multiple Myeloma/Ovarian Cancer				
---------------------------------	--	--	--	--

Ritalin®/FOCALIN™:

FOCALIN: ADHD				
Ritalin LA®: ADHD				
FOCALIN XR™: ADHD				

Anti-Inflammatory:

apremilast (CC-10004): Psoriasis				
apremilast (CC-10004): Psoriatic Arthritis				
apremilast (CC-10004): Behcet's Syndrome				
CC-11050: Inflammatory				

Kinase Inhibitors:

JNK 930: Fibrotic Diseases				
----------------------------	--	--	--	--

Ligase Inhibitors:

Ubiquitin Ligase: Cancer				
--------------------------	--	--	--	--

Stem Cells and Tissue Products:

Lifebank USA: Private Stem Cell Banking				
HPP: Transplants				
PDA-001: Autoimmune/Cancer				
BIOVANCE and Acelagraft™				

MGCD0103:


Solid Tumors (w/ gemcitabine)				
Hematologic Malignancies				
w/ Vidaza in MDS/AML				
w/ Vidaza in lymphoma				

AMRUBICIN®:

SCLC				
w/ Cisplatin for SCLC				
Breast Cancer				

ACTIVIN INHIBITOR

ACE-011 Cancer-related bone loss				
----------------------------------	--	--	--	--



The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.